Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Randomized, Open-label, Active-controlled, Parallel, Multiple-dose Study Comparing the Safety, Pharmacokinetics and Efficacy of Dehydratech Cannabidiol and Glucagon-like Peptide 1 Agonists Alone and in Combination, in Overweight or Obese, pre-and Type 2 Diabetic Participants.

NCT06648031 is registered in ClinicalTrials.gov with Lexaria Bioscience Corp. as lead sponsor.

NCT NCT06648031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06648031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Randomized, Open-label, Active-controlled, Parallel, Multiple-dose Study Comparing the Safety, Pharmacokinetics and Efficacy of Dehydratech Cannabidiol and Glucagon-like Peptide 1 Agonists Alone and in Combination, in Overweight or Obese, pre-and Type 2 Diabetic Participants.
Lead sponsor
Lexaria Bioscience Corp.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2024
Completion date
July 31, 2025
Enrollment
148 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type2diabetes